AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Neurogene Statistics
Share Statistics
Neurogene has 20.98M shares outstanding. The number of shares has increased by 63.23% in one year.
Shares Outstanding | 20.98M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 61.46% |
Owned by Institutions (%) | n/a |
Shares Floating | 16.17M |
Failed to Deliver (FTD) Shares | 6.74K |
FTD / Avg. Volume | 1.69% |
Short Selling Information
The latest short interest is 914.19K, so 4.36% of the outstanding shares have been sold short.
Short Interest | 914.19K |
Short % of Shares Out | 4.36% |
Short % of Float | 5.65% |
Short Ratio (days to cover) | 7.15 |
Valuation Ratios
The PE ratio is -6.84 and the forward PE ratio is -8.62.
PE Ratio | -6.84 |
Forward PE | -8.62 |
PS Ratio | 0 |
Forward PS | 816.3 |
PB Ratio | 1.34 |
P/FCF Ratio | -4.8 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Neurogene Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.72, with a Debt / Equity ratio of 0.
Current Ratio | 8.72 |
Quick Ratio | 8.72 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | -4631.92 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -27.48%.
Return on Equity (ROE) | -0.2% |
Return on Assets (ROA) | -0.16% |
Return on Capital (ROIC) | -27.48% |
Revenue Per Employee | 0 |
Profits Per Employee | -399.09K |
Employee Count | 91 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -44.27% in the last 52 weeks. The beta is 0, so Neurogene 's price volatility has been lower than the market average.
Beta | 0 |
52-Week Price Change | -44.27% |
50-Day Moving Average | 29.76 |
200-Day Moving Average | 36.53 |
Relative Strength Index (RSI) | 31 |
Average Volume (20 Days) | 398.04K |
Income Statement
Revenue | n/a |
Gross Profit | -3.26M |
Operating Income | -55.58M |
Net Income | -36.32M |
EBITDA | -52.29M |
EBIT | n/a |
Earnings Per Share (EPS) | -2.83 |
Balance Sheet
The company has 148.21M in cash and 16.25M in debt, giving a net cash position of 131.96M.
Cash & Cash Equivalents | 148.21M |
Total Debt | 16.25M |
Net Cash | 131.96M |
Retained Earnings | -187.15M |
Total Assets | 164.12M |
Working Capital | 127.85M |
Cash Flow
In the last 12 months, operating cash flow was -51.42M and capital expenditures -321.00K, giving a free cash flow of -51.74M.
Operating Cash Flow | -51.42M |
Capital Expenditures | -321.00K |
Free Cash Flow | -51.74M |
FCF Per Share | -4.03 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
NGNE does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -15.72% |
FCF Yield | -13.71% |
Analyst Forecast
The average price target for NGNE is $60, which is 233.3% higher than the current price. The consensus rating is "Buy".
Price Target | $60 |
Price Target Difference | 233.3% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Stock Splits
The last stock split was on Dec 19, 2023. It was a backward split with a ratio of 1:4.
Last Split Date | Dec 19, 2023 |
Split Type | backward |
Split Ratio | 1:4 |
Scores
Altman Z-Score | 8.24 |
Piotroski F-Score | 1 |